Management of advanced gastric cancer: An overview of major findings from meta-analysis

Qi, Xiaolong; Liu, Yanna; Wang, Wei; Cai, Danxian; Li, Wende; Hui, Jialiang; Liu, Chuan; Zhao, Yuliang; Li, Guoxin

doi:10.18632/oncotarget.12102

Cited by 30 publications

(26 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Regarding the long‐term prognosis of laparoscopic gastrectomy for advanced gastric cancer, we found one multicenter retrospective study, three reviews, and two meta‐analyses (Table ) published after the guidelines. They showed that there were no marked differences in the long‐term prognosis of laparoscopic and open gastrectomy.…”

Section: Consensus Guidelines For Enhanced Recovery After Gastrectomymentioning

confidence: 99%

Current status of the “enhanced recovery after surgery” program in gastric cancer surgery

Yamagata

Yoshikawa

Yura

et al. 2019

Annals of Gastroent Surgery

View full text Add to dashboard Cite

Since the late 1990s, perioperative care through the enhanced recovery after surgery (ERAS, European Society for Clinical Nutrition and Metabolism [ESPEN]) program has spread. ERAS protocols aim to reduce surgical complications, improving postoperative outcomes and thereby saving resources by addressing various clinical elements through a multidisciplinary approach or based on evidence. In the field of gastric cancer, the philosophy of ERAS has gradually become accepted and, in 2014, consensus guidelines for enhanced recovery after gastrectomy were published. These guidelines consist of “procedure‐specific” guidelines and “general (not procedure‐specific) enhanced recovery items.” In this review, we focused on the procedure‐specific guidelines and tried to update the contents of every element of the procedure‐specific guidelines. The procedure‐specific guidelines consist of the following eight elements: “Preoperative nutrition,” “Preoperative oral pharmaconutrition,” “Access (of gastrectomy),” “Wound catheters and transversus abdominis plane block,” “Nasogastric/Nasojejunal decompression,” “Perianastomotic drains,” “Early postoperative diet and artificial nutrition,” and “Audit.” On reviewing papers supporting these elements, it was reconfirmed that the recommendations of the guidelines are pertinent and valid. Four meta‐analyses concerning the evaluation of ERAS protocols for gastric cancer were included in this review. Every study showed that the ERAS protocol reduced the cost and duration of hospital stay without increasing surgical complication rates, suggesting that ERAS is effective for gastric cancer surgery. However, it cannot be said that ERAS has achieved full penetration in Japan because most evidence is established in Western countries. Future studies must focus on developing a new ERAS protocols appropriate to Japanese conditions of gastric cancer.

show abstract

Section: Consensus Guidelines For Enhanced Recovery After Gastrectomymentioning

confidence: 99%

Current status of the “enhanced recovery after surgery” program in gastric cancer surgery

Yamagata

Yoshikawa

Yura

et al. 2019

Annals of Gastroent Surgery

View full text Add to dashboard Cite

show abstract

“…The overall 5‐year survival rate is only 20% (Bang, ; Eric Van Cutsem, ). Cisplatin (CDDP)‐based chemotherapy is a widely used chemotherapeutic regimen to treat gastric cancer (Helleday, Petermann, Lundin, Hodgson, & Sharma, ; Qi et al, ). However, some patients are insensitive to CDDP treatment and develop resistance and cause recurrence and metastasis.…”

Section: Introductionmentioning

confidence: 99%

[6]‐Gingerol enhances the cisplatin sensitivity of gastric cancer cells through inhibition of proliferation and invasion via PI3K/AKT signaling pathway

Yang

Zha

Luo

et al. 2019

Phytotherapy Research

View full text Add to dashboard Cite

Cisplatin‐based chemotherapy is a widely used chemotherapeutic regimen for gastric cancer; however, drug resistance limits its efficacy. [6]‐Gingerol has been found to exhibit anticancer effects. Here, we aim to explore the potential of [6]‐gingerol in combination with cisplatin as a new regimen for gastric cancer. CCK‐8 assay and colony formation assay were used to determine the effect of [6]‐gingerol in combination with cisplatin on cell viability of gastric cancer cells. Flow cytometry was performed to assess cell cycle distribution. Wound‐healing assay and transwell invasion assay were conducted to examine the migration and invasion abilities. Cell cycle and invasion‐related proteins and mRNAs, as well as PI3K/AKT signaling proteins, were assessed by western blotting and quantitative real‐time polymerase chain reaction. Combination of [6]‐gingerol with cisplatin inhibited cell viability and enhanced cell cycle arrest at G1 phase compared with cisplatin alone. The combination treatment inhibited cell migration and invasion ability and decreased cyclin D1, cyclin A2, matrix metalloproteinase‐9, p‐PI3K, AKT, and p‐AKT protein expressions and increased P21 and P27 mRNA levels. Our study demonstrates that [6]‐gingerol enhances the cisplatin sensitivity of gastric cancer cells and that the mechanisms involve G1 phase arrest, migration and invasion suppression via PI3K/AKT signaling pathway.

show abstract

“…Laparoscopic distal gastrectomy had been proved to be safe for advanced GC 2. Even with advanced systematic therapy, the 5-year overall survival of patients with late-stage GC was not >20% 3. Therefore, it is of great significance to investigate the mechanism of GC progression and metastasis.…”

Section: Introductionmentioning

confidence: 99%

Circ-104916 is downregulated in gastric cancer and suppresses migration and invasion of gastric cancer cells

Jin¹,

Li²,

Zhang³

et al. 2017

OTT

Self Cite

View full text Add to dashboard Cite

Circular RNAs are a large class of noncoding RNA that have shown huge capabilities as gene regulators. Recent evidence suggest that circular RNAs are associated with many diseases, especially cancer. However, little attention has been focused on the expression and function of circular RNA in gastric cancer (GC). In this study, we demonstrate that the expression of circ-104916 is downregulated in GC tissues and cell lines. A lower expression of circ-104916 appeared in deeper invasion depth, higher tumor stage and more frequent lymphatic metastasis patients. Overexpression of circ-104916 effectively inhibited the proliferation, migration and invasion abilities of GC cells in vitro. Western blot showed that circ-104916 overexpression upregulated E-cadherin and downregulated N-cadherin, Vimentin and Slug, indicating that circ-104916 was involved in the epithelial–mesenchymal transition process. Our results revealed that circ-104916 might be a novel potential tumor suppressor and biomarker of GC.

show abstract

Management of advanced gastric cancer: An overview of major findings from meta-analysis

Cited by 30 publications

References 57 publications

Current status of the “enhanced recovery after surgery” program in gastric cancer surgery

Current status of the “enhanced recovery after surgery” program in gastric cancer surgery

[6]‐Gingerol enhances the cisplatin sensitivity of gastric cancer cells through inhibition of proliferation and invasion via PI3K/AKT signaling pathway

Circ-104916 is downregulated in gastric cancer and suppresses migration and invasion of gastric cancer cells

Contact Info

Product

Resources

About